Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions

Immunity

Volumn 43, Issue 6, 2015, Pages 1040-1051

  Patel, Dhavalkumar D ^a   Kuchroo, Vijay K ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; STAT3 PROTEIN;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CANDIDA ALBICANS; CELL DIFFERENTIATION; CELL FUNCTION; CELLULAR IMMUNITY; CROHN DISEASE; CYTOGENETICS; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; IMMUNE DEFICIENCY; MUCOCUTANEOUS CANDIDIASIS; MULTIPLE SCLEROSIS; MYCOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENICITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STOP CODON; TH17 CELL; TISSUE INJURY; AUTOIMMUNITY; GENETICS; IMMUNOLOGY; MUTATION;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; MUTATION; TH17 CELLS;

EID: 84963607000     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.12.003     Document Type: Review

References (90)

1. Al Khatib S., Keles S., Garcia-Lloret M., Karakoc-Aydiner E., Reisli I., Artac H., Camcioglu Y., Cokugras H., Somer A., Kutukculer N., et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol 2009, 124:342-348. 348 e341-345.
2. Baeten D.L., Kuchroo V.K. How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat. Med. 2013, 19:824-825.
3. Bettelli E., Kuchroo V.K. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together. J. Exp. Med. 2005, 201:169-171.
4. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
5. Björses P., Halonen M., Palvimo J.J., Kolmer M., Aaltonen J., Ellonen P., Perheentupa J., Ulmanen I., Peltonen L. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am. J. Hum. Genet. 2000, 66:378-392.
6. Boisson B., Wang C., Pedergnana V., Wu L., Cypowyj S., Rybojad M., Belkadi A., Picard C., Abel L., Fieschi C., et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 2013, 39:676-686.
7. Busse W.W., Holgate S., Kerwin E., Chon Y., Feng J., Lin J., Lin S.L. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 2013, 188:1294-1302.
8. Carvalho A., Giovannini G., De Luca A., D'Angelo C., Casagrande A., Iannitti R.G., Ricci G., Cunha C., Romani L. Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell. Mol. Immunol. 2012, 9:276-286.
9. Ciofani M., Madar A., Galan C., Sellars M., Mace K., Pauli F., Agarwal A., Huang W., Parkurst C.N., Muratet M., et al. A validated regulatory network for Th17 cell specification. Cell 2012, 151:289-303.
10. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
11. de Beaucoudrey L., Puel A., Filipe-Santos O., Cobat A., Ghandil P., Chrabieh M., Feinberg J., von Bernuth H., Samarina A., Jannière L., et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 2008, 205:1543-1550.
12. de Beaucoudrey L., Samarina A., Bustamante J., Cobat A., Boisson-Dupuis S., Feinberg J., Al-Muhsen S., Jannière L., Rose Y., de Suremain M., et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010, 89:381-402.
13. Dick A.D., Tugal-Tutkun I., Foster S., Zierhut M., Melissa Liew S.H., Bezlyak V., Androudi S. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013, 120:777-787.
14. Drewniak A., Gazendam R.P., Tool A.T.J., van Houdt M., Jansen M.H., van Hamme J.L., van Leeuwen E.M.M., Roos D., Scalais E., de Beaufort C., et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 2013, 121:2385-2392.
15. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
16. Faragó B., Magyari L., Sáfrány E., Csöngei V., Járomi L., Horvatovich K., Sipeky C., Maász A., Radics J., Gyetvai A., et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann. Rheum. Dis. 2008, 67:248-250.
17. Felson D.T., LaValley M.P. The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing. Arthritis Res. Ther. 2014, 16:101.
18. Ferretti S., Bonneau O., Dubois G.R., Jones C.E., Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J. Immunol. 2003, 170:2106-2112.
19. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
20. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 2009, 9:556-567.
21. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Mazurov V., Aelion J.A., Lee S.H., Codding C.E., Kellner H., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann. Rheum. Dis. 2013, 72:863-869.
22. Genovese M.C., Greenwald M., Cho C.S., Berman A., Jin L., Cameron G.S., Benichou O., Xie L., Braun D., Berclaz P.Y., Banerjee S. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2014, 66:1693-1704.
23. Ghoreschi K., Laurence A., Yang X.P., Tato C.M., McGeachy M.J., Konkel J.E., Ramos H.L., Wei L., Davidson T.S., Bouladoux N., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature 2010, 467:967-971.
24. Gordon K.B., Langley R.G., Gottlieb A.B., Papp K.A., Krueger G.G., Strober B.E., Williams D.A., Gu Y., Valdes J.M. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Invest. Dermatol. 2012, 132:304-314.
25. Gordon K.B., Duffin K.C., Bissonnette R., Prinz J.C., Wasfi Y., Li S., Shen Y.K., Szapary P., Randazzo B., Reich K. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N. Engl. J. Med. 2015, 373:136-144.
26. Griffiths C.E., Reich K., Lebwohl M., van de Kerkhof P., Paul C., Menter A., Cameron G.S., Erickson J., Zhang L., Secrest R.J., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015, 386:541-551. UNCOVER-2 and UNCOVER-3 investigators.
27. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., Antoni C., Draelos Z., Gold M.H., Durez P., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010, 2:52ra72. Psoriasis Study Group, Rheumatoid Arthritis Study GroupRheumatoid Arthritis Study Group, Uveitis Study GroupUveitis Study Group.
28. Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., Wehkamp J., Feagan B.G., Yao M.D., Karczewski M., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700. Secukinumab in Crohn's Disease Study Group.
29. Hüffmeier U., Lascorz J., Böhm B., Lohmann J., Wendler J., Mössner R., Reich K., Traupe H., Kurrat W., Burkhardt H., Reis A. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 2009, 129:355-358.
30. Huppler A.R., Verma A.H., Conti H.R., Gaffen S.L. Neutrophils Do Not Express IL-17A in the Context of Acute Oropharyngeal Candidiasis. Pathogens 2015, 4:559-572.
31. Jetten A.M. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl. Recept. Signal. 2009, 7:e003.
32. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
33. Kimball A.B., Gordon K.B., Langley R.G., Menter A., Chartash E.K., Valdes J., Investigators A.B.T.P.S. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch. Dermatol. 2008, 144:200-207. ABT-874 Psoriasis Study Investigators.
34. Kisand K., Bøe Wolff A.S., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., Ersvaer E., Perheentupa J., Erichsen M.M., Bratanic N., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 2010, 207:299-308.
35. Kopp T., Riedl E., Bangert C., Bowman E.P., Greisenegger E., Horowitz A., Kittler H., Blumenschein W.M., McClanahan T.K., Marbury T., et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015, 521:222-226.
36. Korn T., Bettelli E., Gao W., Awasthi A., Jäger A., Strom T.B., Oukka M., Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
37. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M.T., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 1999, 103:1345-1352.
38. Krueger J.G., Ferris L.K., Menter A., Wagner F., White A., Visvanathan S., Lalovic B., Aslanyan S., Wang E.E., Hall D., et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015, 136:116-124 e117.
39. Langley R.G., Elewski B.E., Lebwohl M., Reich K., Griffiths C.E., Papp K., Puig L., Nakagawa H., Spelman L., Sigurgeirsson B., et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N. Engl. J. Med. 2014, 371:326-338. ERASURE Study Group, FIXTURE Study GroupFIXTURE Study Group.
40. Lebwohl M., Strober B., Menter A., Gordon K., Weglowska J., Puig L., Papp K., Spelman L., Toth D., Kerdel F., et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N. Engl. J. Med. 2015, 373:1318-1328.
41. Lee J.S., Tato C.M., Joyce-Shaikh B., Gulan F., Cayatte C., Chen Y., Blumenschein W.M., Judo M., Ayanoglu G., McClanahan T.K., et al. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity 2015, 43:727-738.
42. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L.T., Gordon K.B. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674. PHOENIX 1 study investigators.
43. Letko E., Yeh S., Foster C.S., Pleyer U., Brigell M., Grosskreutz C.L., Group A.A.S. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 2015, 122:939-948. AIN457A2208 Study Group.
44. Liu Y., Helms C., Liao W., Zaba L.C., Duan S., Gardner J., Wise C., Miner A., Malloy M.J., Pullinger C.R., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008, 4:e1000041.
45. Liu L., Okada S., Kong X.F., Kreins A.Y., Cypowyj S., Abhyankar A., Toubiana J., Itan Y., Audry M., Nitschke P., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 2011, 208:1635-1648.
46. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
47. Ma C.S., Chew G.Y., Simpson N., Priyadarshi A., Wong M., Grimbacher B., Fulcher D.A., Tangye S.G., Cook M.C. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 2008, 205:1551-1557.
48. Maxwell J.R., Zhang Y., Brown W.A., Smith C.L., Byrne F.R., Fiorino M., Stevens E., Bigler J., Davis J.A., Rottman J.B., et al. Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. Immunity 2015, 43:739-750.
49. Mease P.J., Genovese M.C., Greenwald M.W., Ritchlin C.T., Beaulieu A.D., Deodhar A., Newmark R., Feng J., Erondu N., Nirula A. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 2014, 370:2295-2306.
50. Mease P.J., McInnes I.B., Kirkham B., Kavanaugh A., Rahman P., van der Heijde D., Landewé R., Nash P., Pricop L., Yuan J., et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N. Engl. J. Med. 2015, 373:1329-1339. FUTURE 1 Study Group.
51. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., Kanno Y., Spalding C., Elloumi H.Z., Paulson M.L., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
52. Minegishi Y., Saito M., Morio T., Watanabe K., Agematsu K., Tsuchiya S., Takada H., Hara T., Kawamura N., Ariga T., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006, 25:745-755.
53. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 2012, 11:763-776.
54. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 2009, 361:888-898.
55. Mitsdoerffer M., Lee Y., Jäger A., Kim H.J., Korn T., Kolls J.K., Cantor H., Bettelli E., Kuchroo V.K. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 2010, 107:14292-14297.
56. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
57. Mozaffari S., Nikfar S., Abdollahi M. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin. Investig. Drugs 2015, 24:949-956.
58. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198:1951-1957.
59. O'Connor W., Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., Kolls J.K., Flavell R.A. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 2009, 10:603-609.
60. Okada S., Markle J.G., Deenick E.K., Mele F., Averbuch D., Lagos M., Alzahrani M., Al-Muhsen S., Halwani R., Ma C.S., et al. IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015, 349:606-613.
61. Ota N., Wong K., Valdez P.A., Zheng Y., Crellin N.K., Diehl L., Ouyang W. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium. Nat. Immunol. 2011, 12:941-948.
62. Ouederni M., Sanal O., Ikinciogullari A., Tezcan I., Dogu F., Sologuren I., Pedraza-Sánchez S., Keser M., Tanir G., Nieuwhof C., et al. Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. Clin. Infect. Dis. 2014, 58:204-213.
63. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., Guzzo C., Hsu M.C., Wang Y., Li S., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684. PHOENIX 2 study investigators.
64. Papp K., Gottlieb A.B., Naldi L., Pariser D., Ho V., Goyal K., Fakharzadeh S., Chevrier M., Calabro S., Langholff W., Krueger G. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J. Drugs Dermatol. 2015, 14:706-714.
65. Pavelka K., Chon Y., Newmark R., Lin S.L., Baumgartner S., Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J. Rheumatol. 2015, 42:912-919.
66. Peters A., Pitcher L.A., Sullivan J.M., Mitsdoerffer M., Acton S.E., Franz B., Wucherpfennig K., Turley S., Carroll M.C., Sobel R.A., et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011, 35:986-996.
67. Plantinga T.S., van der Velden W.J., Ferwerda B., van Spriel A.B., Adema G., Feuth T., Donnelly J.P., Brown G.D., Kullberg B.J., Blijlevens N.M., Netea M.G. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2009, 49:724-732.
68. Poddubnyy D., Hermann K.G., Callhoff J., Listing J., Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann. Rheum. Dis. 2014, 73:817-823.
69. Prando C., Samarina A., Bustamante J., Boisson-Dupuis S., Cobat A., Picard C., AlSum Z., Al-Jumaah S., Al-Hajjar S., Frayha H., et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 2013, 92:109-122.
70. Puel A., Döffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., Cobat A., Ouachée-Chardin M., Toulon A., Bustamante J., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 2010, 207:291-297.
71. Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., Migaud M., Israel L., Chrabieh M., Audry M., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332:65-68.
72. Rahman P., Inman R.D., Gladman D.D., Reeve J.P., Peddle L., Maksymowych W.P. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 2008, 58:1020-1025.
73. Rangel-Moreno J., Carragher D.M., de la Luz Garcia-Hernandez M., Hwang J.Y., Kusser K., Hartson L., Kolls J.K., Khader S.A., Randall T.D. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 2011, 12:639-646.
74. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., Wang Y., Shen Y.K., Doyle M.K., Mendelsohn A.M., Gottlieb A.B. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 2014, 73:990-999. PSUMMIT 2 Study Group.
75. Rouvier E., Luciani M.F., Mattéi M.G., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 1993, 150:5445-5456.
76. Sandborn W.J., Gasink C., Gao L.L., Blank M.A., Johanns J., Guzzo C., Sands B.E., Hanauer S.B., Targan S., Rutgeerts P., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012, 367:1519-1528. CERTIFI Study Group.
77. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H., Ustekinumab M.S.I. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008, 7:796-804. Ustekinumab MS Investigators.
78. Sherlock J.P., Joyce-Shaikh B., Turner S.P., Chao C.C., Sathe M., Grein J., Gorman D.M., Bowman E.P., McClanahan T.K., Yearley J.H., et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat. Med. 2012, 18:1069-1076.
79. Sieper J., Rudwaleit M., Baraliakos X., Brandt J., Braun J., Burgos-Vargas R., Dougados M., Hermann K.G., Landewé R., Maksymowych W., van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 2009, 68(Suppl 2):ii1-ii44.
80. Taylor P.R., Roy S., Leal S.M., Sun Y., Howell S.J., Cobb B.A., Li X., Pearlman E. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat. Immunol. 2014, 15:143-151.
81. Teunissen M.B., Koomen C.W., de Waal Malefyt R., Wierenga E.A., Bos J.D. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 1998, 111:645-649.
82. Thaçi D., Blauvelt A., Reich K., Tsai T.F., Vanaclocha F., Kingo K., Ziv M., Pinter A., Hugot S., You R., Milutinovic M. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J. Am. Acad. Dermatol. 2015, 73:400-409.
83. van de Veerdonk F.L., Plantinga T.S., Hoischen A., Smeekens S.P., Joosten L.A., Gilissen C., Arts P., Rosentul D.C., Carmichael A.J., Smits-van der Graaf C.A., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 2011, 365:54-61.
84. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
85. Wang C., Wu L., Bulek K., Martin B.N., Zepp J.A., Kang Z., Liu C., Herjan T., Misra S., Carman J.A., et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat. Immunol. 2013, 14:72-81.
86. Wang R., Hasnain S.Z., Tong H., Das I., Che-Hao Chen A., Oancea I., Proctor M., Florin T.H., Eri R.D., McGuckin M.A. Neutralizing IL-23 is superior to blocking IL-17 in suppressing intestinal inflammation in a spontaneous murine colitis model. Inflamm. Bowel Dis. 2015, 21:973-984.
87. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
88. Wu C., Yosef N., Thalhamer T., Zhu C., Xiao S., Kishi Y., Regev A., Kuchroo V.K. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013, 496:513-517.
89. Yosef N., Shalek A.K., Gaublomme J.T., Jin H., Lee Y., Awasthi A., Wu C., Karwacz K., Xiao S., Jorgolli M., et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013, 496:461-468.
90. Zielinski C.E., Mele F., Aschenbrenner D., Jarrossay D., Ronchi F., Gattorno M., Monticelli S., Lanzavecchia A., Sallusto F. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012, 484:514-518.